01:26:15

Updates on MDS Classifications

30:25

Case Study 1: Part 1

06:01

About The MDS Foundation (2021 ASH)

14:11

When and how genetic predisposition to MDS should be taken into account in clinical decision making

23:13

Genetically Inspired Classification (Part 1)

05:03

Cast Study 3: Part 3

03:50

Case Study 2: Part 2

05:20

Case Study 1: Part 2

07:56

Can transplantation improve survival rates for older patients with Higher risk MDS?

06:16

When and how genetic predisposition to MDS should be taken into account in clinical decision making

06:56

Genetically-inspired Classification (Part 2)

20:18

Case Study 2: A patient with a myeloid neoplasm and a TP53 mutation

17:01

Case Study 3: An Anemic Patient with CCUS

21:44

Can Transplantation improve survival rates for older patients with Higher risk MDS?

01:22:40

Caring For The Caregiver

01:00:59

MDSR 2024: MDS/MPN

01:55:04

MDSR 2024: Clinical Higher Risk MDS

05:03

MDSR 2024: Closing Ceremony

01:19:29

MDSR 2024: Germline Predisposition

41:26

MDSR 2024: Case Discussion

01:02:47

MDSR 2024: Future Diagnostics

31:06

MDSR 2024: Morphology

01:04:29

MDSR 2024: Clinical Lower Risk MDS - Part 2 Treatments

01:07:11

MDSR 2024: Clinical Lower Risk MDS - Part 1

40:49

MDSR 2024: Lecture Response Criteria

01:02:33

MDSR 2024: Clonal Hematopoiesis/Inflammation

25:06

MDSR 2024: VEXAS Syndrome

28:38

MDSR 2024: WHO2022, ICC, & other classifications

01:38:14

MDSR 2024: Classification, Prognostication Session

16:46

MDSR 2024: Opening Ceremony

01:09:26

MDS 2023: Opening Ceremony & Keynote Lecture

01:53:49

MDS 2023: Nurses Workshop - The Nurse and the MDS Patient Management

01:02:11

MDS 2023: Tito Bastianello & MDSF Young Investigators Awards & Presentations

35:24

MDS 2023: Keynote Lecture

01:04:27

MDS 2023: PS 10 - Innovations in Transplantation and Cellular Immunotherapy for MDS Patients

01:43:46

MDS 2023: PS 9 - CMML and Other Specific Sub Types of MDS and MDS/MPN

02:21

JOE (Journey of Empowerment)

02:21

JOE (Journey of Empowerment)

02:21

Introducing JOE (Journey of Empowerment)

01:24:33

MDS 2023: PS 8 - Outcome Researches

01:38:33

MDS 2023: PS 7 - Non Targeted Approaches for HR MDS

01:31:50

MDS 2023: PS 6 - Druggable mutations and other personalized approaches for the treatment of MDS

01:51:42

MDS 2023: PS 5 - Predisposition to MDS

01:15:52

MDS 2023: PS 4 - Dyserythropoiesis in MDS

01:33:47

MDS 2023: PS 3 - Prognostication and Stratification of MDS

01:24:51

MDS 2023: PS 2 - From Clonal Hematopoiesis to Overt MDS

01:41:50

MDS 2023: PS1 - Dysimmunity, Inflammation and MDS

01:31:13

MDS Clinical Trial Basics & How SparkCures Can Find a Trial that is Right for You

01:58

MDS 2023 Regional Symposium - Dr. Moshe Mittelman

02:05

Don't miss Dr. Nannya's Presentation on Azacitidine Treatment

16:28

Debate II: Should cytoreduction precede transplant?

21:00

Can we do better than HMA in HR-MDS?

13:01

Patient Discussion II

23:56

Patient Discussion I

17:53

Artificial intelligence in MDS practice

24:45

Debate I: ESA - Still the 1st line for LR-MDS?

20:33

Pre MDS states CH, CCUS, ICUS – How to manage in the clinic?

17:44

A classification of myelodysplastic syndromes that aids clinical decision-making

06:32

MDS challenges in 2023

01:33

Don't miss Dr. Bennett's Presentation on Dysplasia, and low risk situations (ICUS, CCUS, CHIP)